For patients undergoing mastectomy, reconstruction represents an important aspect of the treatment plan, with studies consistently demonstrating improvements in qualityof-life indices and cosmetic outcomes with reconstruction. 1 The majority of reconstructions performed after mastectomy for breast cancer are staged expander/implant-based reconstructions. 2 One common strategy used for patients who may require radiation therapy after mastectomy has been initial placement of a subpectoral tissue expander, which subsequently is replaced with a permanent implant months after the completion of radiation therapy. However, during the past few years, immediate direct-to-permanent implant reconstruction is increasingly being used for breast cancer patients undergoing mastectomy. 3 Although outcomes with immediate reconstruction show the technique to be safe and effective, limited data are available on outcomes for patients undergoing post-mastectomy radiation therapy (PMRT) following immediate permanent implant reconstruction. [4] [5] [6] Immediate permanent implant reconstruction offers advantages to patients including the potential for a single reconstructive procedure, but the opportunities of such an approach must be weighed against potential oncologic and toxicity challenges. 7 With respect to radiation therapy, how does immediate direct-to-permanent implant reconstruction change radiation therapy treatment? To understand potential challenges, it is important to understand patient selection and targets for PMRT. Patients offered PMRT traditionally include those with larger tumors (T3 or above) and nodal positivity (N2-3, consideration with N1 disease). 8 As such, treatment targets include the reconstructed chest wall and regional nodes, potentially including the undissected/dissected axilla, supraclavicular fossa, and internal mammary nodes. Although internal mammary radiation was included in the randomized trials evaluating PMRT, controversy over the treatment of internal mammary nodes has lasted for decades. However, the frequency of internal mammary radiation has increased recently, with studies demonstrating a benefit from treatment of the internal mammary nodes as part of regional nodal irradiation. [9] [10] [11] [12] [13] For patients undergoing PMRT without reconstruction, multiple techniques exist for treatment of the chest wall and regional nodes, which can incorporate heart-and lungsparing techniques. 14 Similarly, for patients with sub-pectoral tissue expanders, multiple options exist for delivering PMRT. 14 However, in some cases, the sub-pectoral expander poses challenges for radiation treatment planning, typically where the ipsilateral expander volume and position makes it difficult to treat the internal mammary nodes or where the contralateral expander is inflated such that the medial radiation beam touches the contralateral reconstructed breast. In these cases, the radiation oncologist can ask the breast/plastic surgeon to reduce the volume in the expander and re-scan the patient, allowing for optimization of radiation treatment planning.
However, with immediate reconstruction using permanent implants, challenges may exist regarding radiation planning. 15 In terms of position, immediate permanent implants tend to sit more medially than sub-pectoral expanders. This creates a challenge because standard radiation therapy approaches often do not work in the treatment of the internal mammary nodes. Additionally, immediate implants, when placed pre-pectorally, often are associated with thin skin bridges, as assessed on computed tomography (CT) scans for radiation planning.
Traditional radiation planning for PMRT often includes the use of a material called bolus during parts of treatment, which increases skin dose and as such may increase complications for patients with pre-pectoral implant reconstructions who experience radiation skin toxicity. 5 Additionally, in contrast to tissue expanders, limited options are available postoperatively for adjustment of an immediate implant that is complicating breast radiation planning. In terms of adjustments with radiation therapy technique, limited options are available. Whereas traditional PMRT has been delivered primarily with threedimensional conformal radiation therapy, newer techniques can be used in these situations, including intensity-modulated radiation therapy. However, such approaches will increase the cost of radiation therapy and may lead to increased toxicities. 16, 17 Currently, although initial outcomes are promising, there are limited data comparing reconstructive approaches and outcomes for patients undergoing immediate implants versus sub-pectoral expander-based reconstruction. 18, 19 Smith et al. 20 presented data on 51 patients undergoing immediate implant reconstruction with adjuvant proton therapy. Overall, 8 of the 51 irradiated breasts had reconstruction failure, raising concerns regarding toxicity with this approach.
What opportunities exist to bridge the benefits of immediate implant reconstruction with the challenges associated with patients undergoing PMRT? 21 First and foremost, an informed multi-disciplinary discussion with the patient and their treatment team, including breast surgery, plastic surgery, and radiation oncology, should take place regarding the pros and cons of each reconstruction option based on the patient's disease findings, anatomy, medical history, and personal preferences. For a selected population of patients at high risk of requiring PMRT (e.g., clinically node-positive, T3/4 disease), staged expander/ implant-based approaches may mitigate the challenges associated with radiotherapy planning in the setting of fullvolume, immediate implants. This would allow the radiation oncologist to work with the plastic surgeon to deflate expanders that are limiting radiation therapy planning. The advantages of such an approach is that it provides greater flexibility in treatment planning. However, it requires at least two procedures for the patient.
For patients who prefer immediate implant reconstruction, reconstruction counseling regarding potential challenges with radiation planning and toxicities is essential. Also, in cases with immediate implants and a limited benefit to internal mammary radiation, treatment of the internal mammary nodes can be omitted, which may facilitate radiation therapy planning. Finally, except for cases with positive margins, a chest wall boost has a limited role for patients undergoing PMRT, which may also limit the risk of toxicity. 22 In conclusion, immediate direct-to-permanent implant reconstruction is increasingly used for patients undergoing mastectomy, with clear benefits for patients. For patients requiring radiation therapy, clinicians, including surgeons and radiation oncologists, must work together to develop individualized treatment plans and to discuss potential risks/benefits of reconstruction approaches with patients. Moving forward, radiation therapy techniques will continue to advance in hopes of reducing toxicity and planning concerns for patients with immediate implant reconstructions.
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